Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 407
Selected: 0
NCT IDTitle
NCT03301493Genomic Testing and Resulting Medical Decisions
NCT01686321Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
NCT00952003Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
NCT00612586Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
NCT00544765Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
NCT00079053Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT05839145Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT00150891Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
NCT04144270The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
NCT00676715A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
NCT04400474Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
NCT01652560Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
NCT00855894A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
NCT00752336Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation
NCT02308527Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
NCT05918666National Register of Actionable Mutations
NCT04387994Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.
NCT00738829Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
NCT00483405Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
NCT02389283Reduced Ultrasound Counts in Rheumatoid Arthritis
NCT01847677Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
NCT02499003GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
NCT01208896Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
NCT01306409Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT00484328Ribavirin, Its Dosing Regime
NCT01558167A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
NCT00477048Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity
NCT01502267Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
NCT06068985Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
NCT01660776BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
NCT04363853Tocilizumab Treatment in Patients With COVID-19
NCT02120911Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
NCT04984811NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT01770301Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)
NCT01022541Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
NCT02433522Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
NCT02344472Detect V / CHEVENDO (Chemo vs. Endo)
NCT02899065Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department
NCT00384566A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure
NCT04702256Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
NCT04770272Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
NCT01423695Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer
NCT01472029Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
NCT03197805Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients
NCT01640405Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells
NCT00333437Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
NCT00730769Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
NCT01745965A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.